Project Grant R01CA317515
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $718K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Cancer Institute awarded $740,346 to The University of Texas MD Anderson Cancer Center on September 9, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393), a Project Grant classified as assistance funding. MD Anderson will develop efficient methods for measuring and characterizing genetic interactions in cancer cells using a CRISPR/Cas12a-based multiplexing system called IN4MER, which quantitates genetic interactions with five-fold fewer reagents than...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $667,282 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test dissemination strategies for lung cancer screening education and counseling delivered through existing state tobacco quitlines. The project compares a low-touch strategy (text/email educational materials alone) against a high-touch strategy in which tobacco treatment specialists within...
- The National Cancer Institute awarded MD Anderson Cancer Center a $1.5 million Cooperative Agreement on July 23, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop clinical-grade combinatorial new approach methodologies (NAMs) assays for colorectal cancer treatment decisions. The recipient will validate three core methodologies—in vitro micro-organospheres (MOSs), in silico DL-Reflect, and VirtualCellTherapy—using clinical samples and patient outcomes across...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $706,777 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct IGNITE-TX, a randomized hybrid effectiveness-implementation trial evaluating interventions to increase cascade genetic testing uptake among individuals at risk for hereditary cancer syndromes, particularly hereditary breast and ovarian cancer and Lynch syndrome. The study recruits 700 probands and 1,400...
- This federal Project Grant award, valued at $407,321 and awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research), supports research to investigate alternative splicing and isoform expression as mediators of the genetic etiology of breast cancer. The key objectives are to: Quantify isoform expression and alternative splicing events in breast tissue using novel transcript assemblies from long-read RNA sequencing data. This will involve benchmarking statistical...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $1.361 million on September 19, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a family-centered lifestyle intervention for Black prostate cancer survivors and their caregivers. The award funds a randomized controlled trial of "Together Stronger," a program targeting physical activity and healthy eating among Black prostate cancer survivors and their...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $688,073 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop computational approaches that reconstruct the evolutionary history of cancer metastases. The project, led by Dr. Peter Van Loo, applies molecular archeology of cancer methods—DNA sequencing-based approaches that infer tumor evolutionary history—to metastatic disease. The work will advance understanding of how...
- Federal Cooperative Agreement Award Summary The National Cancer Institute (NCI) awarded a $525,013 Cooperative Agreement to The University of Texas MD Anderson Cancer Center, effective September 1, 2025 through August 31, 2030, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). This award funds translational research to validate blood-based biomarkers for lung cancer risk assessment among individuals with no smoking history. The project will evaluate the predictive...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $500,384 on July 15, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop transfer learning methods that integrate diverse data sources—established risk prediction models, surrogate outcomes, and family medical history—to improve clinical decision-making and cancer risk prediction. The project will develop rank-based transfer learning approaches that leverage relative risk...
- The National Cancer Institute awarded $192,240 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop cancer digital twins that optimize treatment stratification for triple-negative breast cancer. The award funds the establishment of cancer digital twin techniques to integrate real-time clinical and multi-modal data into virtual patient models that predict individual patient responses to neoadjuvant...